Last reviewed · How we verify
NCT05287776
E-cadherin and Integrin Alpha v Beta 1 in Vitiligo
NA trial testing Narrow band UVB in Vitiligo in 15 participants. Status unknown.
1 May 2022
Quick facts
| Lead sponsor | Kasr El Aini Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 1 June 2019 |
| Primary completion | 1 May 2022 |
| Estimated completion | 1 December 2022 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Narrow band UVB
Conditions studied
- Vitiligo — all drugs for Vitiligo →
Sponsor
Kasr El Aini Hospital
Who can join
Adults 18 to 60, any sex, with Vitiligo. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this clinical trial is to study the effect of Narrow Band UVB on E-cadherin and integrin alpha v beta 1 as representatives of adhesion molecules in non-segmental vitiligo in a trial to verify a novel proposed mechanism of Narrow Band UVB. Additionally, specific melanocyte marker (Melan A) will be done to settle the localization of adhesion molecules in relation to melanocytes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05287776
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vitiligo
Currently open trials in the same condition.
- NCT07153666 — A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo · recruiting
- NCT07267273 — Betamethasone Phonophoresis For Vitiligo · NA · recruiting
- NCT07232238 — TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients · active not recruiting
- NCT07532330 — Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo · NA · active not recruiting
- NCT07357870 — A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo · Phase 1 · recruiting
Other Kasr El Aini Hospital trials
Trials by the same sponsor.
- NCT07438652 — Effect of Mediterranean vs Paleolithic Diet on RA Activity, Sarcopenia and QOL: 12-Week RCT · NA · recruiting
- NCT07488039 — Labroplasty in Cases of Anterior Shoulder Instability With Subcritical Glenoid Bone Loss · NA · recruiting
- NCT07274280 — Comparative Evaluation of Ambu AuraGain, LarySeal Pro and I-gel in Pediatric Airway Management for Day-Case Surgery Unde · NA · not yet recruiting
- NCT07348146 — Hand-Sewn vs. Stapled Anastomosis in SADI-S: Early Postoperative Complications. · NA · enrolling by invitation
- NCT07077265 — Comparing Two Different Norepinephrine Infusion Rates for Prophylaxis Against Spinal-induced Hypotension in Elderly · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05287776 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kasr El Aini Hospital
- Last refreshed: 18 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05287776.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing